WHAT IS CLAIMED IS:

1. A compound of the following formula:



wherein

each of R^1 and R^2, independently, is H, halo, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl, optionally substituted with halo, $-OR^a$, C_{1-5} alkyl, substituted aryl, substituted heteroaryl, C_{1-5} haloalkyl, C_{1-5} alkyl-OR^a, -CN, $-C(O)R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^{a'}$, $-C(O)OR^a$, $-C(O)NR^aR^{a'}$, $-NO_2$, $-OC(O)R^a$, $-NR^aC(O)R^{a'}$, $-NR^aC(O)OR^{a'}$, or $-NR^aC(O)NR^{a'}R^{a''}$; in which each of R^a, $R^{a'}$, and $R^{a''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of A_1 and A_2, independently, is C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl, optionally substituted with halo, $-OR^b$, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} alkyl-OR^b, -CN, $-NO_2$, $-C(O)R^b$, $-SR^b$, $-S(O)R^b$, $-S(O)_2R^b$, $-NR^bR^{b'}$, $-C(O)OR^b$, $-C(O)NR^bR^{b'}$, $-NO_2$, $-OC(O)R^{b'}$, $-NR^bC(O)R^{b'}$, $-NR^bC(O)OR^{b'}$, or $-NR^bC(O)NR^{b'}R^{b''}$, provided that if A_1 is heteroaryl, it forms a C-N bond with the imidazolidinone ring; in which each of R^b, $R^{b'}$, and $R^{b''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of X and Y, independently, is $-C(H)(R^c)$, $-C(R^c)(R^{c'})-$, $-NR^{c''}-$, -S-, -S(O)-, $-S(O)_2-$, $-C(H)(OR^d)-$, $-C(H)[OC(O)R^d]-$, $-C(H)(NR^dR^{d'})-$, $-C(H)[NR^dC(O)R^{d'}]-$, $-C(H)[NR^dC(O)OR^{d'}]$, $-C(H)[NR^dC(O)NR^{d'}R^{d''}]$, -C(H)(SH)-, $-C(H)(SR^d)-$, $-C(H)(SOR^d)-$, $-C(H)(SO_2R^d)-$, C_{6-12} aryl, cyclyl, heterocyclyl, heteroaryl, alkenyl, alkynyl,  or  ; in which each of R^c and $R^{c'}$, independently, is halo, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} hydroxyalkyl, C_{1-5} aminoalkyl, C_{1-5} alkoxy, C_{1-5} aryloxy, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl; $R^{c''}$ is C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} hydroxyalkyl, C_{1-5} aminoalkyl, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl; and each of R^d, $R^{d'}$, and $R^{d''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of m, n, and p, independently, is 0, 1, 2, 3, 4, or 5; and

each of x and y, independently, is 0 or 1, provided that at least one of x and y is 1.

2. The compound of claim 1, wherein x is 1, y is 0, and p is 0.

3. The compound of claim 2, wherein R^1 is H.

4. The compound of claim 3, wherein A_1 is pyridin-4-yl.

5. The compound of claim 4, wherein A_2 is aryl.

6. The compound of claim 5, wherein A_2 is phenyl.

7. The compound of claim 6, wherein R^2 is substituted at position 4 of phenyl.

8. The compound of claim 7, wherein R^2 is C_{6-12} aryl or heteroaryl, optionally substituted with halo, C_{1-5} alkyl, or C_{1-5} haloalkyl.

9. The compound of claim 8, wherein X is $-C(H)(R^c)-$, $-C(R^c)(R^{c'})-$, $-NR^{c''}-$, or phenyl.

10. The compound of claim 9, wherein X is $-C(H)(CH_3)-$.

11. The compound of claim 10, wherein R^2 is phenyl, 1,2,4-oxadiazolyl, tetrazolyl, or thienyl, optionally substituted with halo or C_{1-5} alkyl.

12. The compound of claim 11, wherein R^2 is 4-chlorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 5-methyl-1,2,4-oxadiazolyl, 5-ethyl-1,2,4-oxadiazolyl, 3-ethyl-tetrazolyl, or 5-chlorothien-2-yl.

13. The compound of claim 12, wherein the sum of m and n is 4.

14. The compound of claim 9, wherein X is $-C(CH_3)(CH_3)-$.

15. The compound of claim 14, wherein R^2 is phenyl, 1,2,4-oxadiazolyl, tetrazolyl, or thienyl, optionally substituted with halo or C_{1-5} alkyl.

16. The compound of claim 15, wherein R^2 is 4-chlorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 5-methyl-1,2,4-oxadiazolyl, 5-ethyl-1,2,4-oxadiazolyl, 3-ethyl-tetrazolyl, or 5-chlorothien-2-yl.

17. The compound of claim 16, wherein the sum of m and n is 4.

18. The compound of claim 9, wherein X is $-N(CH_3)-$.

19. The compound of claim 18, wherein R^2 is phenyl, 1,2,4-oxadiazolyl, tetrazolyl, or thienyl, optionally substituted with halo or C_{1-5} alkyl.

20. The compound of claim 19, wherein R^2 is 4-chlorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 5-methyl-1,2,4-oxadiazolyl, 5-ethyl-1,2,4-oxadiazolyl, 3-ethyl-tetrazolyl, or 5-chlorothien-2-yl.

21. The compound of claim 20, wherein the sum of m and n is 4.

22. The compound of claim 9, wherein X is phenyl.

23. The compound of claim 22, wherein R^2 is phenyl, 1,2,4-oxadiazolyl, tetrazolyl, or thienyl, optionally substituted with halo or C_{1-5} alkyl.

24. The compound of claim 23, wherein R^2 is 4-chlorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 5-methyl-1,2,4-oxadiazolyl, 5-ethyl-1,2,4-oxadiazolyl, 3-ethyl-tetrazolyl, or 5-chlorothien-2-yl.

25. The compound of claim 24, wherein the sum of m and n is 4.

26. The compound of claim 9, wherein X is $-C(H)(CF_3)-$.

27. The compound of claim 26, wherein R^2 is phenyl, 1,2,4-oxadiazolyl, tetrazolyl, or thienyl optionally substituted with halo or C_{1-5} alkyl.

28. The compound of claim 27, wherein R^2 is 4-chlorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 5-methyl-1,2,4-oxadiazolyl, 5-ethyl-1,2,4-oxadiazolyl, 3-ethyl-tetrazolyl, or 5-chlorothien-2-yl.

29. The compound of claim 28, wherein the sum of m and n is 4.

30. The compound of claim 8, wherein R^2 is phenyl optionally substituted with halo.

31. The compound of claim 30, wherein X is $-C(H)(R^c)-$, $-C(R^c)(R^{c'})-$, $-NR^{c''}-$, or phenyl.

32. The compound of claim 31, wherein X is $-N(CH_3)-$, $-C(H)(CH_3)-$, $-C(H)(CF_3)-$, $-C(CH_3)(CH_3)-$, or phenyl.

33. The compound of claim 8, wherein X is 1,2,4-oxadiazoly1,2,4-oxadiazolyl, tetrazolyl, or thienyl, optionally substituted with halo or C_{1-5} alkyl.

34. The compound of claim 33, wherein X is, $-C(H)(R^c)-$, $-C(R^c)(R^{c'})-$, $-NR^{c''}-$or phenyl.

35. The compound of claim 34, wherein X is $-N(CH_3)-$, $-C(H)(CH_3)-$, $-C(H)(CF_3)-$, $-C(CH_3)(CH_3)-$, or phenyl.

36. The compound of claim 1, wherein A_2 is phenyl.

37. The compound of claim 36, wherein R^1 is H.

38. The compound of claim 37, wherein A_1 is pyridin-4-yl.

39. The compound of claim 1, wherein R^1 is H.

40. The compound of claim 39, wherein A_1 is pyridin-4-yl.

41. The compound of claim 1, wherein the compound is


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

or .

42. A method of treating infection by enterovirus, comprising administering to a subject in need thereof an effective amount of a compound of the following formula:



wherein

each of R^1 and R^2, independently, is H, halo, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl, optionally substituted with halo, $-OR^a$, C_{1-5} alkyl, substituted aryl, substituted heteroaryl, C_{1-5} haloalkyl, C_{1-5} alkyl-OR^a, -CN, $-C(O)R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^{a'}$, $-C(O)OR^a$, $-C(O)NR^aR^{a'}$, $-NO_2$, $-OC(O)\ R^a$, $-NR^aC(O)\ R^{a'}$, $-NR^aC(O)OR^{a'}$, or $-NR^aC(O)NR^{a'}R^{a''}$; in which each of R^a, $R^{a'}$, and $R^{a''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of A_1 and A_2, independently, is C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl, optionally substituted with halo, $-OR^b$, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} alkyl-OR^b, -CN, $-NO_2$, $-C(O)R^b$, $-SR^b$, $-S(O)R^b$, $-S(O)_2R^b$, $-NR^bR^{b'}$, $-C(O)OR^b$, $-C(O)NR^bR^{b'}$, $-NO_2$, $-OC(O)\ R^{b'}$, $-NR^bC\ (O)\ R^{b'}$, $-NR^bC(O)OR^{b'}$, or $-NR^bC(O)NR^{b'}R^{b''}$, provided that if A_1 is heteroaryl, it forms a C-N bond with the imidazolidinone ring; in which each of R^b, $R^{b'}$, and $R^{b''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of X and Y, independently, is $-C(H)(R^c)$, $-C(R^c)(R^{c'})$-, $-NR^{c''}$-, -S-, -S(O)-, $-S(O)_2$-, $-C(H)(OR^d)$-, $-C(H)[OC(O)R^d]$-, $-C(H)(NR^dR^{d'})$-, $-C(H)[NR^dC(O)R^{d'}]$-, $-C(H)[NR^dC(O)OR^{d'}]$, $-C(H)[NR^dC(O)NR^{d'}R^{d''}]$, -C(H)(SH)-, $-C(H)(SR^d)$-, $-C(H)(SOR^d)$-, $-C(H)(SO_2R^d)$-, C_{6-12} aryl, cyclyl, heterocyclyl, heteroaryl, alkenyl, alkynyl,  or  ; in which each of R^c and $R^{c'}$, independently, is halo, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} hydroxyalkyl, C_{1-5} aminoalkyl, C_{1-5} alkoxy, C_{1-5} aryloxy, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl; $R^{c''}$ is C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} hydroxyalkyl, C_{1-5} aminoalkyl, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl; and each of R^d, $R^{d'}$, and $R^{d''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of m, n, and p, independently, is 0, 1, 2, 3, 4, or 5; and

each of x and y, independently, is 0 or 1, provided that at least one of x and y is 1.

43. The method of claim 42, wherein x is 1, y is 0, and p is 0.

44. The method of claim 43, wherein R^1 is H.

45. The method of claim 44, wherein A_1 is pyridin-4-yl.

46. The method of claim 45, wherein A_2 is phenyl.

47. The method of claim 46, wherein R^2 is substituted at position 4 of phenyl.

48. The method of claim 47, wherein R^2 is C_{6-12} aryl or heteroaryl, optionally substituted with halo, C_{1-5} alkyl, or C_{1-5} haloalkyl.

49. The method of claim 48, wherein X is $-C(H)(R^c)-$, $-C(R^c)(R^{c'})-$, $-NR^{c''}-$,or phenyl.

50. The method of claim 49, wherein R^2 is phenyl, 1,2,4-oxadiazolyl, tetrazolyl, or thienyl, optionally substituted with halo or C_{1-5} alkyl.

51. The method of claim 50, wherein R^2 is 4-chlorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 5-methyl-1,2,4-oxadiazolyl, 5-ethyl-1,2,4-oxadiazolyl, 3-ethyl-tetrazolyl, or 5-chlorothien-2-yl.

52. The method of claim 51, wherein the sum of m and n is 4.

53. The method of claim 43, wherein R^1 is H.

54. The method of claim 53, wherein A_1 is pyridin-4-yl.

55. The method of claim 42, wherein the compound is


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,

,

,

,

,

,

;

,

or .

56. A pharmaceutical composition comprising a compound of the following formula:



wherein

each of R^1 and R^2, independently, is H, halo, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl, optionally substituted with halo, $-OR^a$, C_{1-5} alkyl, substituted aryl, substituted heteroaryl, C_{1-5} haloalkyl, C_{1-5} alkyl-OR^a, -CN, $-C(O)R^a$, $-SR^a$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^{a'}$, $-C(O)OR^a$, $-C(O)NR^aR^{a'}$, $-NO_2$, $-OC(O)\ R^a$, $-NR^aC(O)\ R^{a'}$, $-NR^aC(O)OR^{a'}$, or $-NR^aC(O)NR^{a'}R^{a''}$; in which each of R^a, $R^{a'}$, and $R^{a''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of A_1 and A_2, independently, is C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl, optionally substituted with halo, $-OR^b$, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} alkyl-OR^b, -CN, $-NO_2$, $-C(O)R^b$, $-SR^b$, $-S(O)R^b$, $-S(O)_2R^b$, $-NR^bR^{b'}$, $-C(O)OR^b$, $-C(O)NR^bR^{b'}$, $-NO_2$, $-OC(O)\ R^{b'}$, $-NR^bC\ (O)\ R^{b'}$, $-NR^bC(O)OR^{b'}$, or $-NR^bC(O)NR^{b'}R^{b''}$, provided that if A_1 is heteroaryl, it forms a C-N bond with the imidazolidinone ring; in which each of R^b, $R^{b'}$, and $R^{b''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of X and Y, independently, is $-C(H)(R^c)$, $-C(R^c)(R^{c'})$-, $-NR^{c''}$-, -S-, -S(O)-, $-S(O)_2$-, $-C(H)(OR^d)$-, $-C(H)[OC(O)R^d]$-, $-C(H)(NR^dR^{d'})$-, $-C(H)[NR^dC(O)R^{d'}]$-, $-C(H)[NR^dC(O)OR^{d'}]$, $-C(H)[NR^dC(O)NR^{d'}R^{d''}]$, -C(H)(SH)-, $-C(H)(SR^d)$-, $-C(H)(SOR^d)$-, $-C(H)(SO_2R^d)$-, C_{6-12} aryl, cyclyl, heterocyclyl, heteroaryl, alkenyl, alkynyl,  or  ; in which each of R^c and $R^{c'}$, independently, is halo, C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} hydroxyalkyl, C_{1-5} aminoalkyl, C_{1-5} alkoxy, C_{1-5} aryloxy, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl; $R^{c''}$ is C_{1-5} alkyl, C_{1-5} haloalkyl, C_{1-5} hydroxyalkyl, C_{1-5} aminoalkyl, C_{6-12} aryl, C_{6-12} aralkyl, or heteroaryl; and each of R^d, $R^{d'}$, and $R^{d''}$, independently, is H, C_{1-5} alkyl, or aryl;

each of m, n, and p, independently, is 0, 1, 2, 3, 4, or 5; and

each of x and y, independently, is 0 or 1, provided that at least one of x and y is 1; and a pharmaceutically acceptable carrier.

57. The composition of claim 56, wherein R^1 is H, A_1 is pyridin-4-yl, A_2 is phenyl.

58. The composition of claim 57, wherein x is 1; y is 0; p is 0; and R^2 is C_{6-12} aryl or heteroaryl, optionally substituted with halo, C_{1-5} alkyl, or C_{1-5} haloalkyl.

59. The composition of claim 58, wherein X is $-C(H)(R^c)-$, $-C(R^c)(R^{c'})-$, $-NR^{c''}-$, or phenyl.

60. The composition of claim 56, wherein the compound is


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,

,

or .